ArticleProbiotics and antimicrobial proteins2026
Lactobacillus Reuteri L81 Alleviates Intestinal Barrier Damage Induced by Escherichia Coli K99 in Mice by Modulating Gut Microbiota Composition and Metabolic Products.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Enterotoxigenic Escherichia coli (ETEC) is one of the primary pathogenic bacteria causing intestinal diseases and diarrhea in young animals. Probiotics can enhance intestinal barrier function and alleviate the occurrence of intestinal diseases and diarrhea by regulating the composition and metabolic products of the gut microbiota. In preliminary studies, we isolated a strain of Lactobacillus reuteri L81 with good probiotic properties from the rectal feces of healthy calves. This strain was found to alleviate weaning diarrhea in calves and improve immune function and antioxidant capacity. However, it remains unclear whether it can mitigate intestinal barrier damage caused by Escherichia coli K99 by regulating the composition of the gut microbiota and its metabolites. Therefore, this study selected 24 male SPF-grade ICR mice aged 4 weeks, randomly divided into 4 groups (n = 6): control group, ETEC group, low-dose Lactobacillus reuteri L81 group (L_L81 group), and high-dose Lactobacillus reuteri L81 group (H_L81 group). From days 1 to 17 of the experiment, the L_L81 and H_L81 groups were gavaged with 0.2 mL of bacterial suspensions at concentrations of 1 × 10⁸ CFU/mL and 1 × 10⁹ CFU/mL daily, respectively, while the control and ETEC groups were given an equal volume of physiological saline. From days 18 to 22, the ETEC, L_L81, and H_L81 groups were infected daily with 0.2 mL of an ETEC K99 bacterial suspension at a concentration of 5 × 10⁹ CFU/mL, whereas the control group continued to receive physiological saline. The results showed that the intervention of Lactobacillus reuteri L81 could regulate the gene expression levels of tight junction proteins in the colon tissue of mice. Moreover, the intervention with H_L81 group could increase the gene expression levels of Claudin-1 and ZO-1 ( P < 0.05) in the colon tissue of mice. The intervention with L_L81 group can inhibit the expression of IL-1β, MyD88, and TLR4 genes in the colon tissue of mice. The analysis of gut microbiota composition revealed that the intervention with Lactobacillus reuteri L81 exhibited a trend toward increasing microbial richness and diversity. It elevated the relative abundances of Lactobacillus, Prevotellaceae_UCG-001, and Gordonibacter in the mouse colon, while reducing the relative abundance of Salmonella. The non-targeted metabolomics analysis indicated that the intervention with Lactobacillus reuteri L81 has regulatory effects on multiple metabolic pathways, including bile secretion, β-alanine metabolism, glutathione metabolism, and arginine and proline metabolism. In conclusion, Lactobacillus reuteri L81 can alleviate intestinal barrier damage induced by ETEC K99 in mice by modulating the composition and metabolites of the gut microbiota.
Indexed as
Identifiers
41205096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.